Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CSBR 
Champions Oncology Inc (CSBR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: CSBR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.31% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 93.07M USD | Price to earnings Ratio 32.14 | 1Y Target Price 12 |
Price to earnings Ratio 32.14 | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 0.55 | 52 Weeks Range 3.75 - 11.99 | Updated Date 10/23/2025 |
52 Weeks Range 3.75 - 11.99 | Updated Date 10/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 5.19% | Operating Margin (TTM) -3.62% |
Management Effectiveness
Return on Assets (TTM) 6.78% | Return on Equity (TTM) 182.28% |
Valuation
Trailing PE 32.14 | Forward PE 22.88 | Enterprise Value 83533010 | Price to Sales(TTM) 1.64 |
Enterprise Value 83533010 | Price to Sales(TTM) 1.64 | ||
Enterprise Value to Revenue 1.47 | Enterprise Value to EBITDA 18.32 | Shares Outstanding 13788421 | Shares Floating 5200441 |
Shares Outstanding 13788421 | Shares Floating 5200441 | ||
Percent Insiders 26.18 | Percent Institutions 48.17 |
Upturn AI SWOT
Champions Oncology Inc
Company Overview
History and Background
Champions Oncology, Inc. was founded in 2007. It provides technology solutions and personalized approaches to improve the development and use of oncology drugs. The company focuses on leveraging its in-vivo and in-vitro platforms to create patient-derived xenograft (PDX) models for preclinical drug development and translational research.
Core Business Areas
- Patient-Derived Xenograft (PDX) Models: Development and provision of PDX models to pharmaceutical and biotechnology companies for preclinical oncology drug development and testing. These models closely mimic human tumor biology.
- In Vitro Services: Development and provision of in vitro assay systems including cell lines and assay ready cells to pharmaceutical and biotechnology companies for drug development.
- Data Analytics and Bioinformatics: Champions Oncology provides data analytics and bioinformatics services to support research and drug development, including genomic and proteomic data analysis.
Leadership and Structure
Dr. Ronnie Morris is the CEO of Champions Oncology Inc. The company has a management team overseeing operations, research and development, sales, and marketing.
Top Products and Market Share
Key Offerings
- PDX Models: Champions Oncology's PDX models are a core offering, representing a significant portion of their revenue. Market share is difficult to specify precisely but is estimated to be around 20% of the global PDX market. Competitors include Charles River Laboratories (CRL), The Jackson Laboratory and Crown Bioscience. Revenue from this segment is not publicly broken down, but constitutes a substantial portion of their business. The PDX Market is expected to hit 2.5 Billion in 2032.
- TumorGraft Technology: This is a novel service leveraging PDX models. Market share data is not precisely available. Competitors include Charles River Laboratories (CRL), The Jackson Laboratory and Crown Bioscience.
- In Vitro Services: Champions Oncology provides services in developing cell-based assays for drug discovery and development.
Market Dynamics
Industry Overview
The oncology drug development market is experiencing significant growth, driven by increasing cancer incidence and advancements in personalized medicine. The use of preclinical models like PDXs is crucial for evaluating drug efficacy and safety.
Positioning
Champions Oncology is positioned as a leader in providing advanced preclinical oncology solutions, particularly through its PDX models. The company differentiates itself through its extensive model library, data analytics capabilities, and focus on personalized oncology.
Total Addressable Market (TAM)
The total addressable market (TAM) for preclinical oncology models is estimated to be in the billions of dollars, with significant growth expected in the coming years. Champions Oncology is well-positioned to capture a significant portion of this market with its leading PDX platform.
Upturn SWOT Analysis
Strengths
- Extensive PDX model library
- Strong data analytics capabilities
- Focus on personalized oncology
- Proprietary TumorGraft technology
Weaknesses
- Reliance on preclinical oncology market
- Relatively small company size
- Competition from larger players
Opportunities
- Expanding into new therapeutic areas
- Partnerships with pharmaceutical companies
- Growth in personalized medicine
- Increasing use of AI and machine learning
Threats
- Regulatory changes
- Technological advancements by competitors
- Economic downturns affecting research budgets
- Pricing pressure from competitors
Competitors and Market Share
Key Competitors
- CRL
- JAX
- PRZO
Competitive Landscape
Champions Oncology offers advantages in specialized PDX models and bioinformatics but competes with larger companies like Charles River. Its smaller size allows for focus, but also limits resources for large-scale operations.
Major Acquisitions
u0997u09cdu09a8u09c1health Inc.
- Year: 2011
- Acquisition Price (USD millions): 0.3
- Strategic Rationale: Added a team specializing in bioinformatics and biostatistics for the company.
Growth Trajectory and Initiatives
Historical Growth: Champions Oncology has experienced revenue growth driven by adoption of PDX models. Growth is also correlated to increased investment in pre-clinical oncology programs by the pharmaceutical industry.
Future Projections: Analyst projections suggest continued revenue growth, driven by the increasing demand for personalized oncology solutions. Specific revenue and EPS projections are dependent on market conditions and are available from analysts reports. Growth is expected to be dependent on securing more contracts with Pharma and Biotechnology companies.
Recent Initiatives: Recent strategic initiatives may include partnerships with pharmaceutical companies, expansion of its PDX model library, and development of new data analytics capabilities. Also, increased focus in in-vitro services
Summary
Champions Oncology is a growing company in the specialized field of preclinical oncology, particularly known for its PDX models. The company has experienced revenue growth and holds a strong position within its niche. However, it must manage competition and remain adaptable to changes. This market is expected to increase and it should look for more opportunities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Champions Oncology Investor Relations
- Industry Reports
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Market data is approximate and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Champions Oncology Inc
Exchange NASDAQ | Headquaters Hackensack, NJ, United States | ||
IPO Launch date 2003-01-10 | CEO & Director Mr. Robert Brainin | ||
Sector Healthcare | Industry Biotechnology | Full time employees 213 | |
Full time employees 213 | |||
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.